Cargando…

“Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)”

Detalles Bibliográficos
Autores principales:	Rasmussen, Bengt, Göhring, Gudrun, Bernard, Elsa, Nilsson, Lars, Tobiasson, Magnus, Jädersten, Martin, Garelius, Hege, Dybedal, Ingunn, Grønbaek, Kirsten, Ejerblad, Elisabeth, Lorenz, Fryderyk, Flogegård, Max, Marcher, Claus Werenberg, Öster Fernström, Annette, Cavelier, Lucia, Papaemmanuil, Elli, Ebeling, Freja, Kittang, Astrid Olsnes, Nørgaard, Jan Maxwell, Saft, Leonie, Möllgård, Lars, Hellström-Lindberg, Eva
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9061286/ https://www.ncbi.nlm.nih.gov/pubmed/35277655 http://dx.doi.org/10.1038/s41375-022-01537-w

Ejemplares similares

Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial
por: Tobiasson, M, et al.
Publicado: (2014)

Failure to reach hematopoietic allogenic stem cell transplantation in patients with myelodysplastic syndromes planned for transplantation: a population-based study
por: Lindholm, C., et al.
Publicado: (2022)

Therapy-related MDS dissected based on primary disease and treatment—a nationwide perspective
por: Moreno Berggren, Daniel, et al.
Publicado: (2023)

Mutations in histone modulators are associated with prolonged survival during azacitidine therapy
por: Tobiasson, Magnus, et al.
Publicado: (2016)

P506: CLINICAL VALIDATION OF THE NORDIC GUIDELINES FOR GERMLINE TESTING IN MYELOID NEOPLASMS: RESULTS FROM A MULTI-CENTER PROSPECTIVE COHORT STUDY
por: Tesi, Bianca, et al.
Publicado: (2023)

Nordic Guidelines for Germline Predisposition to Myeloid Neoplasms in Adults: Recommendations for Genetic Diagnosis, Clinical Management and Follow-up
por: Baliakas, Panagiotis, et al.
Publicado: (2019)

A new software tool for computer assisted in vivo high-content analysis of transplanted fluorescent cells in intact zebrafish larvae
por: Førde, Jan-Lukas, et al.
Publicado: (2022)

Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications
por: Nilsson, Christer, et al.
Publicado: (2022)

The Possible Diagnostic and Prognostic Use of Systemic Chemokine Profiles in Clinical Medicine—The Experience in Acute Myeloid Leukemia from Disease Development and Diagnosis via Conventional Chemotherapy to Allogeneic Stem Cell Transplantation
por: Reikvam, Håkon, et al.
Publicado: (2013)

A risk score based on real-world data to predict early death in acute promyelocytic leukemia
por: Österroos, Albin, et al.
Publicado: (2022)

Omalizumab alleviates pruritus in myeloproliferative neoplasms
por: Landtblom, Anna Ravn, et al.
Publicado: (2023)

Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine
por: Schlenk, R. F., et al.
Publicado: (2019)

Acute Myeloid Leukemia with the t(8;21) Translocation: Clinical Consequences and Biological Implications
por: Reikvam, Håkon, et al.
Publicado: (2011)

Oral Azacitidine and Cedazuridine Approximate Parenteral Azacitidine Efficacy in Murine Model
por: Ramsey, Haley E., et al.
Publicado: (2020)

Living with outpatient management as spouse to intensively treated acute leukemia patients
por: Jepsen, Lene Østergaard, et al.
Publicado: (2019)

Rehabilitation during intensive treatment of acute leukaemia including allogenic stem cell transplantation: a qualitative study of patient experiences
por: Jepsen, Lene Østergaard, et al.
Publicado: (2019)

Expression patterns of chemokine receptors on circulating T cells from myelodysplastic syndrome patients
por: Sand, Kristoffer Evebø, et al.
Publicado: (2013)

The Systemic Profile of Soluble Immune Mediators in Patients with Myelodysplastic Syndromes
por: Kittang, Astrid Olsnes, et al.
Publicado: (2016)

The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia
por: Fredly, Hanne, et al.
Publicado: (2013)

NSAID consumption and risk of acute myeloid leukemia: a national population-based case-control study
por: Østgård, Lene Sofie Granfeldt, et al.
Publicado: (2018)

Improved outcome in acute myeloid leukemia patients enrolled in clinical trials: A national population-based cohort study of Danish intensive chemotherapy patients
por: Østgård, Lene Sofie Granfeldt, et al.
Publicado: (2016)

The AGILE trial of ivosidenib plus azacitidine versus azacitidine alone: How many limitations is too many?
por: Bhatt, Anjali, et al.
Publicado: (2022)

The Protein Kinase C Agonist PEP005 (Ingenol 3-Angelate) in the Treatment of Human Cancer: A Balance between Efficacy and Toxicity
por: Ersvaer, Elisabeth, et al.
Publicado: (2010)

Safety and efficacy of azacitidine in myelodysplastic syndromes
por: Vigil, Carlos E, et al.
Publicado: (2010)

Azacitidine: No therapeutic response: case report
Publicado: (2020)

Azacitidine in patients with WHO-defined AML – Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group
por: Pleyer, Lisa, et al.
Publicado: (2013)

Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose
por: Jilg, Stefanie, et al.
Publicado: (2019)

The role of azacitidine in the management of myelodysplastic syndromes (MDS)
por: Götze, KS, et al.
Publicado: (2009)

Azacitidine in outpatient treatment – single center experience
por: Rybka, Justyna, et al.
Publicado: (2016)

Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group
por: Pleyer, Lisa, et al.
Publicado: (2014)

Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
por: Sekeres, Mikkael A., et al.
Publicado: (2021)

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
por: Adès, Lionel, et al.
Publicado: (2022)

Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease
por: Tobiasson, Magnus, et al.
Publicado: (2017)

Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
por: Sekeres, Mikkael A., et al.
Publicado: (2021)

G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial
por: Stopka, Tomáš, et al.
Publicado: (2022)

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3(mut+) AML ineligible for intensive chemotherapy
por: Wang, Eunice S., et al.
Publicado: (2022)

Oral vitamin C supplementation to patients with myeloid cancer on azacitidine treatment: Normalization of plasma vitamin C induces epigenetic changes
por: Gillberg, Linn, et al.
Publicado: (2019)

Outcome of therapy-related myeloid neoplasms treated with azacitidine
por: Fianchi, Luana, et al.
Publicado: (2012)

Injection-Site Reaction Following 5-Azacitidine Injection
por: Jun, Hee Jin, et al.
Publicado: (2014)

Azacitidine in Chronic Myelomonocytic Leukemia: An Effective and Manageable Approach
por: Tendas, Andrea, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_icvt9l053a30cul2j26abig723